Glenmark Pharma

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE935A01035
  • NSEID: GLENMARK
  • BSEID: 532296
INR
2,287.00
-12 (-0.52%)
BSENSE

Aug 07, 03:32 PM

BSE+NSE Vol: 4.49 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 780863,
    "name": "Glenmark Pharma",
    "stock_name": "Glenmark Pharma",
    "full_name": "Glenmark Pharmaceuticals Ltd.",
    "name_url": "stocks-analysis/glenmark-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "2,287.00",
    "chg": -12,
    "chgp": "-0.52%",
    "dir": -1,
    "prev_price": "2,299.00",
    "mcapval": "64,539.33 Cr",
    "mcap": "Mid Cap",
    "scripcode": 532296,
    "symbol": "GLENMARK",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE935A01035",
    "curr_date": "Aug 07, 03:32 PM",
    "curr_time": "15:34 PM",
    "last_traded_at": "Aug 07, 03:32 PM IST",
    "bse_nse_vol": "4.49 lacs",
    "exc_status": "Active",
    "traded_date": "Aug 07, 2026",
    "traded_date_str": "2026 08 07",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/glenmark-pharma-780863-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "text": "Part of MojoOne Strategy",
      "type": "SM",
      "url": "https://www.marketsmojo.com/mojopro/stock-of-the-month",
      "ismore": 0,
      "all_data": [],
      "is_blur": 1,
      "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/glenmark-pharma-780863-0&utm_source=Spage_Score_PartofStrategies"
    }
  },
  "news": {
    "results": [
      {
        "title": "Glenmark Pharmaceuticals Ltd. Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-4137038",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/GlenmarkPharmac_technicaldot_4137038.png",
        "date": "2026-08-05 08:04:51",
        "description": "Glenmark Pharmaceuticals Ltd. has experienced a subtle shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Despite this positive directional change, key technical indicators such as the MACD and KST remain mildly bearish on weekly and monthly charts, while moving averages on the daily timeframe signal bullishness. This nuanced technical landscape suggests cautious optimism for investors amid mixed signals."
      },
      {
        "title": "Glenmark Pharmaceuticals Ltd. Technical Momentum Shifts Amid Mixed Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-signals-4134928",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/GlenmarkPharmac_technicaldot_4134928.png",
        "date": "2026-08-04 08:07:14",
        "description": "Glenmark Pharmaceuticals Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Recent technical indicators reveal a complex picture, with bearish signals emerging on weekly and monthly MACD and KST charts, while daily moving averages maintain a mildly bullish outlook. This nuanced technical landscape coincides with a 2.45% decline in the stock price on 4 Aug 2026, reflecting investor caution amid mixed momentum cues."
      },
      {
        "title": "Why is Glenmark Pharmaceuticals Ltd. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-glenmark-pharmaceuticals-ltd-fallingrising-4134244",
        "imagepath": "",
        "date": "2026-08-04 01:27:03",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Short-Term Price Movement and Market Context</strong></p>\n<p>The stock’s recent decline is evident in its underperformance relative to key benchmarks. Over the past week, Glenmark’s shares have slipped by 0.72%, while the Sensex gained 2.35%. Similarly, in the last month, the stock fell 1.41% against the Sensex’s 1.13% rise. On the day in question, the stock touched an intraday low of ₹2,163, marking a 3.15% drop from previous levels. The weighted average price indicates that a larger volume of shares traded closer to this low, signalling selling pressure during the session.</p>\n<p>Further compounding the short-term weakness is the decline in investor participation. Delivery volumes, a key indicator of genuine investor interest, fell sharply by 52.72% compared to the five-day average, droppi..."
      },
      {
        "title": "Glenmark Pharmaceuticals Ltd. Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-4132923",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/GlenmarkPharmac_technicaldot_4132923.png",
        "date": "2026-08-03 08:02:20",
        "description": "Glenmark Pharmaceuticals Ltd. has demonstrated a notable shift in price momentum, moving from a sideways trend to a mildly bullish stance, supported by daily moving averages and monthly bullish indicators. Despite mixed signals from weekly technicals such as MACD and KST, the stock’s recent performance and technical parameters suggest cautious optimism for investors navigating the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Glenmark Pharmaceuticals Gains 1.83%: 5 Key Factors Driving the Week’s Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-gains-183-5-key-factors-driving-the-weeks-momentum-4131705",
        "imagepath": "",
        "date": "2026-08-01 15:09:24",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>27 Jul:</strong> Sharp open interest surge amid mixed market signals</p>\n                    <p><strong>28 Jul:</strong> Technical momentum shifts to mildly bearish</p>\n                    <p><strong>29 Jul:</strong> Upgrade to Buy on strong financials and technical rebound</p>\n                    <p><strong>30 Jul:</strong> Shift to mildly bullish technical momentum with strong returns</p>\n                    <p><strong>31 Jul:</strong> Technical momentum shifts amid mixed signals, sideways trend emerges</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.2..."
      },
      {
        "title": "Glenmark Pharmaceuticals Q1 FY27: Stellar Profit Surge Masks Revenue Growth Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/glenmark-pharmaceuticals-q1-fy27-stellar-profit-surge-masks-revenue-growth-concerns-4131723",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/GlenmarkPharmac_quaterlyResult_4131723.png",
        "date": "2026-08-01 13:18:33",
        "description": "Glenmark Pharmaceuticals Ltd. delivered a remarkable 930.34% year-on-year surge in consolidated net profit to ₹482.92 crores for Q1 FY27 ended June 2026, rebounding dramatically from the ₹46.87 crores reported in the corresponding quarter last year. However, the sequential profit growth of 60.22% from Q4 FY26's ₹301.41 crores reveals a more nuanced picture, as the company navigates margin pressures and operational challenges in its core markets."
      },
      {
        "title": "Glenmark Pharmaceuticals Ltd. Technical Momentum Shifts Amid Mixed Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-signals-4129531",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/GlenmarkPharmac_technicaldot_4129531.png",
        "date": "2026-07-31 08:01:49",
        "description": "Glenmark Pharmaceuticals Ltd. has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend as of late July 2026. Despite a recent downgrade in daily price performance, the company’s technical indicators present a complex picture, with mixed signals from MACD, RSI, Bollinger Bands, and moving averages. This analysis delves into the evolving technical landscape of Glenmark Pharma, contextualising its price action against broader market movements and sectoral trends."
      },
      {
        "title": "Glenmark Pharmaceuticals Upgraded to Buy on Strong Financials and Technical Rebound",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glenmark-pharmaceuticals-upgraded-to-buy-on-strong-financials-and-technical-rebound-4128059",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/GlenmarkPharmac_mojoScore_4128059.png",
        "date": "2026-07-30 08:18:02",
        "description": "Glenmark Pharmaceuticals Ltd. has been upgraded from a Hold to a Buy rating by MarketsMojo as of 29 Jul 2026, reflecting significant improvements across quality, valuation, financial trends, and technical indicators. The mid-cap pharmaceutical company’s robust quarterly performance, attractive valuation metrics, and a shift to a mildly bullish technical trend underpin this positive reassessment."
      },
      {
        "title": "Glenmark Pharmaceuticals Ltd. Shifts to Mildly Bullish Technical Momentum Amid Strong Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-ltd-shifts-to-mildly-bullish-technical-momentum-amid-strong-returns-4127891",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/GlenmarkPharmac_technicaldot_4127891.png",
        "date": "2026-07-30 08:01:57",
        "description": "Glenmark Pharmaceuticals Ltd. has demonstrated a notable shift in price momentum, transitioning from a mildly bearish to a mildly bullish technical trend. This change is underpinned by a combination of positive signals from key technical indicators including MACD, moving averages, and Bollinger Bands, signalling renewed investor confidence in the mid-cap pharmaceutical player."
      }
    ],
    "total": 596,
    "sid": "780863",
    "stock_news_url": "https://www.marketsmojo.com/news/glenmark-pharmaceuticals-780863"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "05-Aug-2026",
      "details": "Transcript of the Earnings Call",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
      "datetime": "03-Aug-2026",
      "details": "Audio recording of Q1 FY 2026-27 Earnings Call held on August 03 2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "01-Aug-2026",
      "details": "The Unaudited (Standalone and Consolidated) Financial Results of the Company for the quarter ended June 30 2026 have been published in Financial Express and Loksatta newspapers on Saturday August 1 2026.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Glenmark Pharmaceuticals Ltd. has declared <strong>250%</strong> dividend, ex-date: 31 Aug 26",
          "dt": "2026-08-31",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Glenmark Pharmaceuticals Ltd. has announced <strong>1:2</strong> stock split, ex-date: 10 Sep 07",
          "dt": "2007-09-10",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views

Why is Glenmark Pharmaceuticals Ltd. falling/rising?

2026-08-04 01:27:03

Short-Term Price Movement and Market Context

The stock’s recent decline is evident in its underperformance relative to key benchmarks. Over the past week, Glenmark’s shares have slipped by 0.72%, while the Sensex gained 2.35%. Similarly, in the last month, the stock fell 1.41% against the Sensex’s 1.13% rise. On the day in question, the stock touched an intraday low of ₹2,163, marking a 3.15% drop from previous levels. The weighted average price indicates that a larger volume of shares traded closer to this low, signalling selling pressure during the session.

Further compounding the short-term weakness is the decline in investor participation. Delivery volumes, a key indicator of genuine investor interest, fell sharply by 52.72% compared to the five-day average, droppi...

Read full news article

Glenmark Pharmaceuticals Gains 1.83%: 5 Key Factors Driving the Week’s Momentum

2026-08-01 15:09:24

Key Events This Week

27 Jul: Sharp open interest surge amid mixed market signals

28 Jul: Technical momentum shifts to mildly bearish

29 Jul: Upgrade to Buy on strong financials and technical rebound

30 Jul: Shift to mildly bullish technical momentum with strong returns

31 Jul: Technical momentum shifts amid mixed signals, sideways trend emerges

stock-recommendationAnnouncement

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

05-Aug-2026 | Source : BSE

Transcript of the Earnings Call

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

03-Aug-2026 | Source : BSE

Audio recording of Q1 FY 2026-27 Earnings Call held on August 03 2026

Announcement under Regulation 30 (LODR)-Newspaper Publication

01-Aug-2026 | Source : BSE

The Unaudited (Standalone and Consolidated) Financial Results of the Company for the quarter ended June 30 2026 have been published in Financial Express and Loksatta newspapers on Saturday August 1 2026.

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Glenmark Pharmaceuticals Ltd. has declared 250% dividend, ex-date: 31 Aug 26

stock-summary
SPLITS

Glenmark Pharmaceuticals Ltd. has announced 1:2 stock split, ex-date: 10 Sep 07

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available